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Summary
The hypoxia-inducible transcription factors HIF-1α and HIF-2α are activated in hypoxic tumor regions. However, their role
in tumorigenesis remains controversial, as tumor growth promoter and suppressor activities have been ascribed to HIF-
1α, while the role of HIF-2α remains largely unknown. Here, we show that overexpression of HIF-2α in rat glioma tumors
enhances angiogenesis but reduces growth of these tumors, in part by increasing tumor cell apoptosis. Moreover, siRNA
knockdown of HIF-2α reduced apoptosis in hypoxic human malignant glioblastoma cells. Furthermore, inhibition of HIF
by overexpression of a dominant-negative HIF transgene in glioma cells or HIF-2a deficiency in teratomas reduced vascu-
larization but accelerated growth of these tumor types. These findings urge careful consideration of using HIF inhibitors
as cancer therapeutic strategies.S I G N I F I C A N C E
The hypoxia-inducible transcription factors HIF-1α and HIF-2α have been proposed to promote tumor growth and angiogenesis. This
has stimulated widespread interest in developing therapeutic strategies to block the HIF-dependent pathways. In the present study,
we provide novel genetic evidence that HIF-2α acts as a tumor suppressor when overexpressed in glioma tumors, while gene
transfer of a HIF inhibitor accelerates—not delays—growth of gliomas. Moreover, genetic inactivation of HIF-2a stimulates ES cell-
derived tumor growth. Thus, based on our findings, we urge careful consideration of the use of HIF inhibitors as cancer therapeutic
strategies.Introduction
Hypoxia is an important environmental determinant of tumor
angiogenesis and growth. Hypoxia-inducible genes contain a
hypoxia response element (HRE), to which the hypoxia-induc-
ible transcription factors (HIF) HIF-1α and HIF-2α bind as a
heterodimer with HIF-1β (Acker and Acker, 2004; Kaelin, 2004;
Liu and Simon, 2004; Maxwell and Salnikow, 2004; Poellinger
and Johnson, 2004; Schofield and Ratcliffe, 2004; Semenza,
2003). In addition, HIFs may also regulate gene transcription,
independently of HRE, by counteracting the transcriptional ac-
tivity of Myc (Koshiji et al., 2004, 2005). Despite structural sim-
ilarities, HIF-1α and HIF-2α have a distinct spatiotemporal ex-
pression pattern and function in vivo. Indeed, HIF-1a-deficient
embryos died of cardiovascular defects (Compernolle et al.,
2003; Iyer et al., 1998; Ryan et al., 1998), while loss of HIF-
2a impaired vascular remodeling and cardiac performance inCANCER CELL : AUGUST 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INembryos (Peng et al., 2000; Tian et al., 1998) and caused neo-
natal respiratory distress (Compernolle et al., 2002) and multi-
organ pathology after birth (Scortegagna et al., 2003).
HIF-1α and HIF-2α are expressed in numerous tumors
(Flamme et al., 1998; Jones et al., 2001; Krieg et al., 2000;
Semenza, 2003; Talks et al., 2000; Wiesener et al., 1998; Xia et
al., 2001). HIF-1α upregulates glycolytic enzymes and angio-
genic factors and is a prognostic marker for a large number of
tumors (Semenza, 2003). The importance of HIF-1α in regulat-
ing tumor angiogenesis was evidenced by the reduced vascu-
larization of HIF-1a-deficient teratomas (Brown et al., 2001;
Carmeliet et al., 1998; Ryan et al., 1998; Tsuzuki et al., 2000;
Yu et al., 2001). However, the effect of HIF-1a deficiency on
tumor growth differs widely. In some studies, loss of HIF-1a
reduced the growth of teratomas and fibrosarcomas (Ryan et
al., 1998, 2000), consistent with reports that HIF inhibitors at-
tenuated tumorigenesis (Kung et al., 2000). However, in otherC. DOI 10.1016/j.ccr.2005.07.003 131
A R T I C L Estudies, HIF-1a-deficient teratomas grew faster, even despite
a reduced tumor vascularization, due to a refractoriness of the
mutant tumor cells to stress-induced apoptosis (Carmeliet et
al., 1998). As a result, HIF-1a-deficient cells preferentially grew
in hypoxic tumor regions (Brown et al., 2001; Yu et al., 2001).
Thus, these genetic studies suggest that HIF-1α may act as
either an oncogene or a tumor suppressor gene.
Even less is known about the role of HIF-2α in cancer, and
the few published reports about its role are conflicting. A num-
ber of studies suggest a tumor-promoting activity of HIF-2α.
Indeed, knockin replacement of HIF-1a by HIF-2a stimulated
teratoma growth due to an increase in angiogenesis and cell
proliferation (Covello et al., 2005), while a stable HIF-2α, but
not HIF-1α, overrode the tumor-suppressing activity of the von
Hippel-Lindau (VHL) protein in renal carcinoma cells (Kondo et
al., 2002; Maranchie et al., 2002). Similarly, HIF-2α but not HIF-
1α overexpression in VHL-defective renal carcinoma cells en-
hanced in vivo tumor growth (Raval et al., 2005). Furthermore,
inhibition of HIF-2α suppressed tumor growth (Kondo et al.,
2003; Zimmer et al., 2004). However, other studies suggest a
tumor suppressor role for HIF-2α. Indeed, overexpression of
HIF-2α has been reported to suppress tumor growth (Blancher
et al., 2000), and loss of the VHL gene, resulting in increased
activation of HIF-1α and HIF-2α, also impaired the growth of
teratomas (Mack et al., 2003). Thus, the precise role of HIF-2α
in tumor biology remains largely unknown. Nonetheless, a bet-
ter understanding of how HIF-2α affects cancer is mandated,
as the interest in developing anti-HIF strategies for cancer
treatment is growing (Giaccia et al., 2003; Poellinger and John-
son, 2004; Semenza, 2003). In this study, we used gain- and
loss-of-function methods to address this question in various
tumor types.
Results
Generation of gliomas overexpressing HIF-2α
To evaluate the role of HIF-2α in tumorigenesis, we performed
gain- and loss-of-function studies, using various tumor models
of mouse, rat, and human origin. We first evaluated whether
overexpression of HIF-2α affected tumor angiogenesis and
growth. For such an experiment to be meaningful, the tumor
cells would need to express endogenous HIF-2α, and the HIF-
2α transgene would need to be overexpressed at physiological
levels (i.e., comparable to the levels observed in hypoxic con-
ditions), as supraphysiological transgene levels might affect tu-
mor cell behavior nonspecifically. We therefore used a rat GS9L
glioma tumor model, which expresses HIF-1α and HIF-2α (Fig-
ures 1A–1E; Figure S1 in the Supplemental Data available with
this article online) and in which angiogenesis is dependent on
hypoxic upregulation of VEGF.
We generated two stably transfected GS9L clones and a
polyclonal pool of retrovirally infected GS9L cells that overex-
press FLAG-tagged HIF-2α. Corresponding control cells were
generated by mock transfection with pcDNA3 or infection with
a LacZ virus. Expression of the HIF-2a transgene was analyzed
by RT-PCR and FLAG immunoreactivity (data not shown), and
by immunodetection of HIF-2α levels (Figures 1A–1E; Figure
S2A; Table S1). These analyses revealed that HIF-2α levels in
transgenic GS9L tumor cells in normoxia were comparable or
slightly higher than those detected in mock-transfected cells in
hypoxia (or exposed to hypoxia mimetics), while hypoxia132upregulated HIF-2α expression levels to a similar extent (by
w30%) in control and HIF-2α-overexpressing cells. In addition,
HIF-2α levels in the transfected GS9L glioma cells were com-
parable to those in various human glioblastoma lines (Figure
S2B). Overexpression of HIF-2α upregulated mRNA transcript
levels of VEGF in normoxia and hypoxia (Figure S2C; Table S2).
For comparison, we also generated GS9L cells that overex-
press HIF-1α at physiological levels (Figure 1E; Figure S1; Ta-
ble S3). As this study focuses on HIF-2α, most data with HIF-
1α were transferred to the Supplemental Data.
HIF-2α stimulates tumor angiogenesis
HIF-2α-overexpressing and control GS9L cells were injected
subcutaneously into nude mice. Histological analysis of estab-
lished tumors revealed that necrosis was only rarely detected
in control tumors (Figure 2A), while HIF-2α-overexpressing tu-
mors had large necrotic areas, which were surrounded by
microvessels and a rim of palisading cells (Figure 2B). The vas-
cular tumor area was increased in HIF-2α-overexpressing tu-
mors (Figures 2D and 2E; Table 1). Compared to control tu-
mors, VEGF levels were increased in HIF-2α tumors, especially
in the perinecrotic cells, as determined by Northern blotting
(data not shown), in situ hybridization (Figures 2G and 2H), and
immunohistochemistry (data not shown), thus indicating that
regulation of tumor angiogenesis by HIF-2α is attributable, at
least in part, to upregulation of VEGF expression. Similar find-
ings were obtained in HIF-1α-overexpressing GS9L tumors
(Figure S3).
HIF-2α reduces tumor growth
Despite their increased vascularization, HIF-2α-overexpressing
tumors grew more slowly. Control tumors grew to large sizes
(>1000 mm3) within 2.5 weeks, when the animals had to be
sacrificed. In contrast, HIF-2α-overexpressing tumors grew
only minimally during the first 2 weeks (<200 mm3) and, even
by 4 weeks, had still not obtained the size that control tumors
obtained after 2 weeks (p < 0.05; n = 10; Figure 3A). Similar
findings were obtained for another HIF-2α-overexpressing
GS9L clone (Figure 3B) and a polyclonal pool of HIF-2α-over-
expressing tumor cells (Figure S4), thus indicating that the re-
duced growth rate of HIF-2α-overexpressing tumors was not
restricted to a single clone or a nonspecific clonal effect. The
growth of HIF-1α-overexpressing tumors was similarly reduced
(Figure S5A).
Increased apoptosis in HIF-2α-expressing tumor cells
Compared to control tumors, apoptosis, quantified by deter-
mining the number of oligonucleosomes per 10 g protein ex-
tract, was increased 5.1 ± 0.6 fold in HIF-2α tumors (p < 0.005;
n = 6). The increased apoptosis of HIF-2α-overexpressing tu-
mors was confirmed by measuring the tumor cell area, immu-
noreactive for activated caspase-3 (aCasp-3), an executer of
apoptosis. In control tumors, aCasp-3-positive tumor cells
were detected only occasionally, while numerous aCasp-3-
positive cells were present in the perinecrotic area in tumors
overexpressing HIF-2α (aCasp-3+ area/optical field, 11.4% ±
1.9%; n = 21; Figures 3C and 3D). Similar findings were ob-
tained for HIF-1α tumors (Figures S5B and S5C).
Protein levels of HIF-2α, both of the endogenous protein as
well as of the transgene product, varied in individual cells, both
in cultured tumor cells in vitro as well as in tumors in vivo—CANCER CELL : AUGUST 2005
A R T I C L EFigure 1. Generation of gliomas overexpressing HIF-2α
A–D: HIF-2α immunostaining of GS9L cells stably transfected with control vector (pcDNA3) or HIF-2α vector (pHIF-2a) in normoxia (A and C) or hypoxia (B
and D). Scale bar, 20 m in A–D.
E: Immunoblotting of HIF-1α and HIF-2α in GS9L cells stably transfected with control vector (pcDNA3), or with HIF-1a or HIF-2a transgenes (Tg) in normoxia
and after treatment with dipyridyl.
F: Immunoblotting of HIF-1α and HIF-2α in human glioblastoma cells (G55), transiently transfected with control siRNA, HIF-1a siRNA, and/or HIF-2a siRNA.presumably because of cellular differences in posttranslational
stabilization. We took advantage of this heterogeneous expres-
sion pattern to examine whether those cells that expressed the
highest HIF-2α levels were also labeled the strongest for
aCasp3, as this might suggest that HIF-2α would switch on
apoptosis in these cells. In both mock-transfected (data not
shown) and HIF-2α-transfected tumor cells, the highest HIF-
2α levels were detected in cultured cells that contained the
highest aCasp-3 levels (Figures 4A–4C). When grown as tu-
mors in vivo, aCasp-3 levels were maximal in a subset of gli-
oma cells in the perinecrotic area that coexpressed abundant
HIF-2α (Figures 4D–4F). These findings were not a peculiarity
of rodent glioma tumors, as HIF-2α protein levels were also
maximal in pseudopalisading cells in the perinecrotic area in
human glioblastoma multiforme tumors (Figure 4G). Impor-
tantly, induction of apoptosis, assayed by TUNEL or aCasp-3
immunostaining, was also maximal in the pseudopalisading
cells expressing maximal HIF-2α protein levels (Figures 4H
and 4I).
HIF-2α regulates tumor cell apoptosis
Even though the above findings show that elevated HIF-2α
levels are correlated with increased tumor cell apoptosis, they
do not necessarily establish a causal role of HIF-2α in tumor
cell apoptosis. To address this question in more detail, we per-
formed gain- or loss-of-HIF-2α function studies in cultured tu-
mor cells. Overexpression of HIF-2α reduced the accumulation
of cultured GS9L glioma cells. At 5 days after plating a compa-
rable number of cells, HIF-2α-overexpressing cells accumu-
lated at only 29% ± 2% of the number of mock-transfectedCANCER CELL : AUGUST 2005cells (p < 0.005; n = 6). The reduced in vitro cell accumulation
was, at least in part, attributable to an increase in apoptosis.
Indeed, compared to control cells, apoptosis was increased in
HIF-2α-overexpressing cells in normoxic and hypoxic condi-
tions (Table 2). The increased apoptosis in HIF-2α-overex-
pressing cells was confirmed by staining for TUNEL (Figures
3F and 3G) and activated caspase-3 (Figures 3I and 3J). Apo-
ptosis was also increased in the polyclonal pool of HIF-2α-
overexpressing tumor cells (Supplemental Results). Similar
findings were obtained after overexpression of HIF-1α in GS9L
tumor cells (Figures S5D–S5G).
To further underscore a possible causal role of HIF-2α in
apoptosis, we studied whether knockdown of HIF-2α, using
siRNA, affected apoptosis of human glioblastoma tumor cells.
Immunoblotting revealed that knockdown of HIF-1a or HIF-2a
lowered (but did not completely eliminate) HIF-1α or HIF-2α
protein levels (Figure 1F). Compared to normoxia, hypoxia in-
creased apoptosis of cultured tumor cells by w1.50-fold (Table
3). In both lines, knockdown of HIF-2α reduced tumor cell apo-
ptosis in hypoxic conditions. A similar effect was observed
when using siRNA to knock down the expression of HIF-1α,
with the greatest effect resulting from a concomitant knock-
down of HIF-1α and HIF-2α (Table 3). Thus, these over- and
underexpression studies demonstrate that HIF-2α functions as
a tumor suppressor gene, not only in rodent but also in human
glioma tumors.
HIF inhibition promotes tumor growth of gliomas despite
reduced vascularization
Inhibition of HIF-1α has been proposed as a novel strategy to
block tumor growth (Kung et al., 2000; Ratcliffe et al., 2000;133
A R T I C L EFigure 2. HIF-2α promotes tumor angiogenesis, whereas HIF inhibition re-
duces tumor angiogenesis
Microscopic analysis of GS9L tumors, stably transfected with control vector
(pcDNA3) or constructs expressing HIF-2α (pHIF-2a) or dominant-negative
HIF (pHIF-dn).
A–C: H&E staining showed the presence of large necrotic zones (N) in HIF-
2α-overexpressing (B) tumors, but not or much less in control (A) tumors.
HIF-dn tumors had micronecrotic regions (C).
D–F: CD34 staining (red) revealed more vascularization in HIF-2α-overex-
pressing (E) than control (D) tumors; in contrast, vascularization in HIF-dn
tumors (F) was decreased.
G–I: In situ VEGF mRNA staining (black dots). In agreement with the vascu-
larization patterns, HIF-2α-overexpressing tumors (H) showed high VEGF
mRNA levels, whereas control tumors (G) showed moderate levels and HIF-
dn tumors (I) showed low levels of VEGF.
Scale bar, 250 m in A–C; 100 m in D–I.Zhong et al., 2000). Considering that overexpression of HIF-2α
or HIF-1α retarded tumor growth, we evaluated whether inhibi-
tion of HIF-2α and HIF-1α would stimulate tumor angiogenesis
and growth. Therefore, we generated both single clones (stable
transfection) and a polyclonal pool (lentiviral infection) of GS9L
cells overexpressing a FLAG-tagged dominant-negative-acting
HIF (HIF-dn) that comprises the amino-terminal residues 24–
325 of HIF-2α, lacks the DNA binding and transactivation do-
mains, and blocks the activity of both HIF-1α and HIF-2α (El-
vert et al., 2003). Compared to control cells, VEGF levels were
significantly reduced in cells overexpressing the HIF-dn con-
struct in normoxia and hypoxia (Figure S2C; Table S2).
Compared to controls, HIF-dn-expressing tumors, injected
subcutaneously into nude mice, had multiple micronecrotic
areas (Figure 2C). The vessel density and total vessel per tumor
area were significantly decreased in HIF-dn tumors (Figure 2F;
Table 1)—a likely cause why micronecrosis occurred in these134tumors. VEGF mRNA (Figure 2I) and protein expression (data
not shown) were also attenuated in HIF-dn tumors. Growth of
monoclonal and polyclonal HIF-dn tumors was accelerated al-
ready at 1 week after inoculation (p < 0.05; n = 10; Figures 3A
and 3B; Figure S4).
We also evaluated whether reduced apoptosis might explain
the accelerated growth of HIF-dn tumors. Interestingly, despite
the existence of multiple micronecrotic areas, only few aCasp+
cells were detected in the perinecrotic tumor border. Unfortu-
nately, however, the degree of apoptosis in the control tumor
was too low to reliably detect any significant differences with
the HIF-dn tumor (Figure 3E). We therefore examined whether
we could detect any effect of HIF-dn on apoptosis of cultured
monoclonal and polyclonal tumor cells in vitro. When counting
the number of oligonucleosomes (Table 2), staining for 3#-hydrox-
ylated DNA fragments (TUNEL) (Figure 3H) or activated cas-
pase-3 (Figure 3K), or counting by flow cytometry the percen-
tage of annexin V-positive propidium iodide-negative cells
(Supplemental Results), no differences in apoptosis were de-
tected between control and HIF-dn-transfected cells, cultured
under normoxic conditions—presumably because the degree
of apoptosis was minimal under normoxia. In hypoxic condi-
tions, apoptosis was increased, but notably, apoptosis was
lower in HIF-dn than in control cells (Table 2; Supplemental
Results). Taken together, inhibition of HIF-2α (and HIF-1α) by a
dominant-negative HIF-dn decreased apoptosis of tumor cells
in vitro, thereby likely promoting tumor growth in vivo.
Reduced vascularization of HIF-2a-deficient
ES cell-derived tumors
Since the dominant-negative HIF construct inhibits both HIF-
1α and HIF-2α, we also evaluated whether specific loss of HIF-
2a alone would affect tumor angiogenesis and growth. We
therefore used HIF-2a-deficient (HIF-2a−/−) embryonic stem
(ES) cells (Brusselmans et al., 2001) and evaluated the vascu-
larization and growth of wild-type (wt) and HIF-2a−/− ES cell-
derived tumors, injected subcutaneously into nude mice. Mac-
roscopic inspection after dissecting the tumors at 5 weeks
after inoculation revealed that wt tumors appeared dark red
and bled profusely, while HIF-2a−/− tumors were pale and failed
to bleed. When counting the total number of all vessels on tis-
sue sections, we found no differences in vascular density in wt
and HIF-2a−/− tumors (CD34-positive vessels/mm2, 190 ± 20
in HIF-2a−/− tumors versus 160 ± 10 in wt tumors; p = 0.13; n =
10). Nonetheless, clear genotypic differences were detectable,
when the vessels were categorized according to their size. Wt
tumors contained large vessels and “blood lakes” in addition
to medium-sized and small vessels (Figures 5A and 5C), while
HIF-2a−/− tumors only contained smaller vessels (Figures 5B
and 5D). The density of small blood vessels (diameter <35 m)
was comparable in wt and HIF-2a−/− tumors (vessels/mm2,
180 ± 20 in HIF-2a−/− tumors versus 140 ± 10 in wt tumors;
p = 0.09; n = 10). In contrast, medium-sized (diameter 35–90
m) and large blood vessels (diameter >90 m) were signifi-
cantly underrepresented in HIF-2a−/− tumors (medium-sized
and large vessels/mm2, 8 ± 3 and 0.33 ± 0.21 in HIF-2a−/−
tumors versus 17 ± 1 and 2.6 ± 0.8 in wt tumors; p < 0.05; n =
10). As a result, the total vessel area per tumor area was re-
duced in HIF-2a−/− tumors (CD34+ vessel area per tumor area,
6.1% ± 0.4% in HIF-2a−/− tumors versus 10.5% ± 1.4% in wtCANCER CELL : AUGUST 2005
A R T I C L ETable 1. Effects of HIF-2α on vascularization of GS9L tumors
Transgene All vessels Small-sized vessels Medium-sized vessels Large-sized vessels
Vessel area (percentage) pcDNA3 7.2 ± 0.4 1.3 ± 0.2 2.2 ± 0.2 3.7 ± 0.4
HIF-2a 8.8 ± 0.6* 1.2 ± 0.1 1.9 ± 0.2 5.8 ± 0.8*
HIF-dn 3.6 ± 0.5* 0.4 ± 0.03* 0.8 ± 0.1* 2.3 ± 0.4*
Vessels/mm2 pcDNA3 190 ± 19 120 ± 15 50 ± 5 23 ± 1
HIF-2a 190 ± 17 120 ± 15 43 ± 5 26 ± 2
HIF-dn 70 ± 7* 40 ± 4* 19 ± 2* 13 ± 3*
Mean vessel area (m2) pcDNA3 400 ± 40 100 ± 10 450 ± 10 1600 ± 100
HIF-2a 500 ± 70 100 ± 10 440 ± 10 2200 ± 200*
HIF-dn 500 ± 50 100 ± 10 440 ± 10 1900 ± 130
GS9L glioma tumor lines were transfected with pcDNA3 (mock), HIF-2a, or HIF-dn. The vessel area was expressed as a percentage of the total tumor area analyzed.
Vessel area and density and mean vessel area are represented for all vessels (all) or per category of vessels: small (0–250 m2), medium (250–750 m2), and large
(>750 m2). The data represent the mean ± SEM (n = 7–8). *p < 0.05 versus pcDNA3.ume and tumor oxygenation were analyzed by intravital micro- cant differences were observed in the total amount of vessels,
Figure 3. HIF-2α reduces tumor growth, whereas HIF inhibition promotes tumor growth
A and B: Growth rate of tumors derived from GS9L cells, stably transfected with control vector (pcDNA3) or with constructs expressing HIF-2α (pHIF-2a) or
a dominant-negative HIF (pHIF-dn). A and B display two separate experiments, using the same control and pHIF-dn tumor clone but different individual
HIF-2α-overexpressing tumor clones. Data represent mean ± SEM (n = 10). *p < 0.05 versus pcDNA3.
C–K: Apoptosis in GS9L cells and GS9L cell-derived tumors, stably transfected with control vector (pcDNA3) or with constructs expressing HIF-2α (pHIF-2a)
or a dominant-negative HIF (pHIF-dn). C–E: In contrast to HIF-dn (E) and control tumors (C), HIF-2α-overexpressing tumors (D) showed excessive staining for
activated caspase-3 (red staining), indicating that HIF-2α induced tumor cell apoptosis. TUNEL staining (F–H, green) and activated caspase-3 staining
(I–K, green) of stably transfected GS9L cells cultured under hypoxia in vitro revealed that overexpression of HIF-2α (G and J) induced activation of cas-
pase-3 and apoptosis in GS9L glioma cell. Scale bar, 100 m in C–E; 50 m in F–K.tumors; p = 0.008; n = 10). Taken together, vascularization was
significantly impaired in HIF-2a−/− tumors.
To analyze whether the decreased vascularization in the HIF-
2a−/− tumors resulted in reduced blood supply, vascular vol-CANCER CELL : AUGUST 2005scopy. Therefore, wt or HIF-2a−/− tumors were implanted in a
dorsal skin chamber, and the tumor vasculature was visualized
using fluorescence microscopy and epi-illumination of an intra-
venously injected fluorescent dye (FITC-dextran). No signifi-135
A R T I C L EFigure 4. HIF-2α regulates tumor cell apoptosis
A–C: Coexpression of HIF-2α and activated caspase-3. Immunostainings
for HIF-2α (A, red), activated caspase-3 (B, green), and merged (HIF-2α/
aCasp-3) (C, yellow) stainings on GS9L cells in vitro, stably transfected with
a construct expressing HIF-2α (pHIF-2a), showed that HIF-2α and activated
caspase-3 were coexpressed in the same cells, indicating that HIF-2α in-
duces apoptosis.
D and E: Tumors derived from GS9L cells, stably transfected with a construct
expressing HIF-2α (pHIF-2a), showed excessive staining (red) of HIF-2α (D)
and activated caspase-3 (E) in perinecrotic regions.
F: Double immunostaining of GS9L tumors, stably transfected with a con-
struct expressing HIF-2α (pHIF-2a), for aCasp-3 (green) and HIF-2α (red) re-
veals coexpression in the same tumor cells (yellow color after merging).
G–I: HIF-2α (G), activated caspase-3 (H), and TUNEL (I) staining in human
glioblastoma multiforme tumors. HIF-2α protein levels were highest in the
pseudopalisading cells in the perinecrotic area (red staining), which
showed maximal induction of apoptosis, as assayed by activated cas-
pase-3 immunostaining (red) or TUNEL (brown/black staining), thereby con-
firming the colocalization of HIF-2α and apoptosis.
Scale bar, 10 m in A–C and F; 75 m in D, E, G, H, and I.136Table 2. Effects of HIF-2α and HIF-dn on apoptosis of GS9L clones
Transgene Normoxia Hypoxia
Mock 1.00 ± 0.02 2.06 ± 0.12+
HIF-2α (clone 1) 3.49 ± 0.33+ 5.47 ± 0.14*
HIF-2α (clone 2) 2.06 ± 0.09+ 4.36 ± 0.6*
HIF-dn 0.92 ± 0.03 1.27 ± 0.09*
Apoptosis was quantified by measuring the amount of oligonucleosomes. The
data (mean ± SEM; n = 4) are expressed as the fold induction (or reduction)
obtained by normalization of the data relative to the data obtained in the mock-
transfected cells in normoxia. +p < 0.05 versus control (normoxia).*p < 0.05
versus control (hypoxia).but the mean vessel diameter was significantly smaller in HIF-
2a−/− than wt tumors (Figures 5E–5G). Also, the pO2 was 30%
lower in HIF-2a−/− than in wt tumors, likely as a result of the
impaired vascularization (Figure 5G). Quantitative RT-PCR re-vealed that transcript levels of VEGF, but not of other angio-
genic genes, were lower in HIF-2a−/− tumors (Table S4), sug-
gesting that the reduced tumor vascularization was largely
attributable to the reduced VEGF levels.
HIF-2a−/− tumors grow faster than wt tumors
We had anticipated that HIF-2a−/− ES cell tumors would grow
more slowly because of their reduced vascularization. Surpris-
ingly, however, HIF-2a−/− tumors grew faster than wt tumors.
By 3 weeks, HIF-2a−/− tumors already tended to be larger than
wt tumors (Figure 5H), but by 5 weeks, HIF-2a−/− tumors were
twice as large as wt tumors (Figure 5H). The increased growth
of HIF-2a−/− tumors might be attributable, at least in part, to
reduced apoptosis, which was significantly lower in HIF-2a−/−
than wt tumors at 5 weeks after inoculation (oligonucleosomes
per mg tumor protein, 540 ± 70 for HIF-2a−/− tumors versus
1270 ± 190 for wt tumors; p = 0.016; n = 5). Similar observa-
tions were made using different wt and HIF-2a−/− ES cell
clones (data not shown).
Discussion
Little is known about the function of HIF-2α in cancer. Here, we
report that overexpression of HIF-2α enhanced glioma tumor
vascularization but impaired tumor growth, in part because of
an increase in tumor cell apoptosis. Moreover, elevated expres-
sion of HIF-2α coincided with apoptosis in human malignant
glioblastoma multiforme tumors, while inhibition of HIF-2α by
siRNA attenuated hypoxic cell apoptosis. Furthermore, gene
transfer of a dominant-negative HIF mutant, which inhibits the
activity of HIF-2α (and HIF-1α), or genetic loss of HIF-2α ac-
celerated tumor growth—even despite reduced tumor vascu-
larization.
Role of HIF-2α in tumor vascularization
Our genetic data that tumor vascularization was increased by
overexpression of HIF-2α and reduced by loss or inhibition of
HIF-2α indicate that HIF-2α regulates tumor vascularization.
This effect was, at least in part, attributable to a reduction in
VEGF production. Teratomas that lack HIF-1a or the HRE in
the VEGF promoter are also less vascularized due to reduced
VEGF levels (Carmeliet et al., 1998; Ryan et al., 1998; Tsuzuki
et al., 2000). Blocking the interaction of HIF-1α with the tran-
scriptional coactivator p300 or dysregulation of the HIF path-
way by 2ME2 also reduced tumor vessel density (Kung et al.,
2000; Mabjeesh et al., 2003). Thus, all these findings indicate
that not only HIF-1α, but also HIF-2α, regulates tumor vascu-CANCER CELL : AUGUST 2005
A R T I C L ETable 3. Effect of siRNA-mediated knockdown of HIF-1α and HIF-2α on hypoxia-induced apoptosis in human glioblastoma cell lines
Cell line Normoxia control Hypoxia control Hypoxia/HIF-1α-kd Hypoxia/HIF-2α-kd Hypoxia/HIF-1α/HIF-2α-kd
G55 1.00 ± 0.009 1.54 ± 0.008+ 0.71 ± 0.005* 0.89 ± 0.007* 0.66 ± 0.007*
G141 1.00 ± 0.008 1.43 ± 0.01+ 1.33 ± 0.02* 1.33 ± 0.016* 1.13 ± 0.007*
Human glioblastoma cell lines G55 and G141 were transiently transfected with control siRNA (mock) or with a siRNA directed to HIF-1a, HIF-2a, or a combination of
both (kd, knockdown). Apoptosis was quantified by measuring the amount of oligonucleosomes. The data (mean ± SEM; n = 4) are expressed as the fold induction (or
reduction) obtained by normalization of the data relative to the data obtained in the control mock under normoxia. +p < 0.05 versus control (normoxia).*p < 0.05 versus
control (hypoxia).ates tumor growth (this study and Carmeliet et al., 1998).human melanoma cells growing in tumor regions devoid of a
Figure 5. Genetic inactivation of HIF-2α reduces
angiogenesis but promotes growth of ES cell-
derived tumors
A–D: H&E staining revealed the presence of
large vascular structures (arrows) in 5-week-old
wt (HIF-2a+/+) tumors (A), whereas HIF-2a−/− tu-
mors appeared much less vascularized (B). En-
dothelial cell staining for CD34 showed the pres-
ence of both capillaries and small vessels
(arrowheads) as well as larger vascular struc-
tures (arrows) in wt tumors (C), and only smaller
vessels (arrowheads) in HIF-2a−/− tumors (D).
E–G: By intravital microscopy, HIF-2a−/− tumors
(F) had a smaller vessel diameter and a re-
duced vascular volume than wt tumors (E). G:
Vascularization parameters and oxygenation
are shown in the table (mean ± SEM; n = 4). p
values: Mann-Whitney U test.
H: Growth rate of wt and HIF-2a−/− tumors: after
3 weeks, no significant difference was observed
between wt and HIF-2a−/− tumors; however, af-
ter 5 weeks HIF-2a−/− tumors were larger than wt
tumors. Mean ± SEM (n = 55–71). *p < 0.05 ver-
sus wt.
Scale bar, 250 m in A–D; 25 m in E and F.larization via upregulation of VEGF. Obviously, we cannot ex-
clude the possibility that HIF-1α and HIF-2α regulate the ex-
pression of additional angiogenic genes. An outstanding
question is whether inhibition or deficiency of HIF-2a resulted
in a partial normalization of the abnormal tumor vasculature,
which would be expected to result in an increase in tumor per-
fusion and growth.
Role of HIF-2α in tumor growth
We observed that loss of HIF-2a or suppression of HIF by a
dominant-negative mutant stimulated the growth of teratomas
and gliomas, even despite their reduced vascularization. Such
a reduced vascular dependence was also observed for HIF-1a-
deficient teratomas but, importantly, also for subpopulations ofCANCER CELL : AUGUST 2005vascular supply (Yu et al., 2001). The increased growth of HIF-
2a null or HIF-inhibited tumors was attributable, at least in part,
to a reduction in tumor cell apoptosis. These in vivo data ex-
tend our previous in vitro data that HIF-2α regulates stress-
induced ES cell apoptosis (Brusselmans et al., 2001). The HIF-
dn construct blocks both HIF-1α and HIF-2α, and thus, the
enhanced growth of HIF-dn tumors is likely attributable to the
suppression of both HIFs. In line with these findings, siRNA
knockdown of HIF-1α or HIF-2α, and especially a combined
knockdown of HIF-1α and HIF-2α, attenuated hypoxia-induced
apoptosis of human glioblastoma cells, suggesting that both
factors cooperate. Further evidence for a tumor suppressor
role of these HIFs is deduced from our present and previous
findings that overexpression of HIF-1α or HIF-2α suppresses
tumor growth, while loss or inhibition of these factors acceler-137
A R T I C L EHypoxia-inducible factors: A more complex
role than anticipated?
Thus far, all studies, including the present, reported a positive
role of HIF-1α, HIF-2α, and HIF-1β in tumor vascularization via
upregulation of VEGF expression. They differ, however, widely
in their reports on the role of these factors in tumor growth.
Most studies documented that tumors express relatively high
levels of HIF-1α, especially when growing more aggressively
(Semenza, 2002), and that tumor growth (Ryan et al., 1998,
2000; Zimmer et al., 2004) or patient prognosis of various tu-
mor types including breast (Dales et al., 2005), lung (Giatroma-
nolaki et al., 2001), colorectal (Yoshimura et al., 2004), and cer-
vical cancer (Bachtiary et al., 2003) correlated with the
expression levels of HIF-1α or HIF-2α. Moreover, loss of HIF-
1a, suppression of HIF by a dominant-negative HIF-1α, or
pharmacological inhibition of HIF-1α by chemotin or topotecan
impaired the growth of various cancers (Chen et al., 2003; Iyer
et al., 1998; Kung et al., 2004; Maltepe et al., 1997; Rapisarda
et al., 2004; Ryan et al., 1998; Stoeltzing et al., 2004).
In contrast, other studies did not report such an oncogenic
activity of HIF-1α. Indeed, increased activation of the HIF path-
way in VHL-deficient tumors or expression of a stable HIF-1α
variant in renal carcinoma cells slowed down tumor growth
(Mack et al., 2003; Maranchie et al., 2002; Raval et al., 2005).
HIF-1α also upregulated the levels of the cell cycle inhibitors
p21CIP1 and p27KIP1, explaining why growth of VHL-deficient
fibrosarcomas was decreased (Mack et al., 2005). Furthermore,
escape from stress-induced cellular death contributed to the
uncontrolled growth of HIF-1a null teratomas despite their re-
duced vascularization (Carmeliet et al., 1998). In mixed tumors
that contained both wt and HIF-1a-deficient ES cells, only HIF-
1a null cells were able to survive in areas distant from tumor
vessels (Brown et al., 2001; Yu et al., 2001). Also, patients with
HIF-1α-positive nonsmall cell lung carcinomas showed in-
creased tumor apoptosis and survived longer than patients
with HIF-1α-negative carcinomas (Volm and Koomagi, 2000).
Expression of HIF-1α in head-and-neck squamous cell carci-
noma was associated with increased patient survival (Beasley
et al., 2002). Another study reported that HIF-1α/HIF-2α levels
were inversely correlated with the growth of human breast can-
cer cells and that HIF-2α overexpression impaired the growth
of these tumors (Blancher et al., 2000).
How can we reconcile these apparently conflicting results?
First, it is well known that HIF-1α and HIF-2α are required for
the survival and differentiation of many nonmalignant cell types
(Compernolle et al., 2002, 2003; Iyer et al., 1998; Peng et al.,
2000; Ryan et al., 1998; Scortegagna et al., 2003; Tian et al.,
1998), but it is also known that activation of the HIF pathway
can induce growth arrest or death of primary cells, such as
developing thymocytes and chondrocytes (Biju et al., 2004;
Schipani et al., 2001). HIFs exert such proapoptotic activity by
stabilizing p53, through a Bnip3/Nix-dependent mechanism, or
by altering the expression of Bcl-2 and caspase family mem-
bers (Greijer and van der Wall, 2004). While these dual activities
of the HIFs may seem, at first sight, conflicting, they may, in
fact, be necessary to allow the cell to respond optimally to
hypoxia. Indeed, through the induction of angiogenesis and
glycolysis, activation of HIF gives cells a growth advantage in
hypoxia, but the induction of growth arrest is also to the cell’s
advantage to survive when the oxygen supply is limited (Koshiji
and Huang, 2004). That these dual HIF-related activities are138operational in tumors is evidenced by findings that, despite an
increase in cell proliferation, HIF-1a-deficient hepatoma growth
was impaired because of an even greater apoptosis rate (Leek
et al., 2005). It has been proposed that tumor cells employ
such a “stop-and-go” strategy to maintain growth and survival.
However, how hypoxic cells strike a balance between these
divergent HIF activities remains an outstanding question.
Clearly, the overall effect on tumor growth is determined by the
relative oncogenic or tumor-suppressive activity of the HIFs.
We speculate that the role of HIF-1α or HIF-2α in the growth/
survival versus arrest/apoptosis decision during hypoxia may
be influenced by a variety of genetic or environmental mecha-
nisms. For example, oncogenes such as Src and Ras affect
cell survival during hypoxia by upregulating HIF-1α (Chen et
al., 2000). The pH and cell cycle are also involved, as hypoxia-
induced apoptosis or accumulation of p53 requires acidosis
(Pan et al., 2004; Schmaltz et al., 1998), while cells in S phase
are more sensitive to hypoxia (Amellem and Pettersen, 1991).
Interestingly, acidosis increases HIF-1α levels by nuclear se-
questration of pVHL (Mekhail et al., 2004). Other questions are
whether variations in cell density, degree of hypoxia, cell type,
or perhaps even the relative HIF levels determine the onco-
genic or tumor suppressor role of the HIF pathways. Alterna-
tively, HIFs may determine clonal selection of tumor cell types,
as observed in HIF-1a null tumors (Carmeliet et al., 1998).
Since HIF-1α and HIF-2α differ in their spatiotemporal expres-
sion pattern, individual genetically unstable tumor cells that
have lost HIF alone or in combination with another tumor sup-
pressor gene may be prone to clonal selection and overgrowth.
Such a mechanism is supported by evidence that p53-deficient
tumor cells are clonally selected and overgrow wt cells in hyp-
oxic tumor regions (Graeber et al., 1996). Finally, the tumor
stroma and surrounding tissue influence the role of HIFs in can-
cer, as illustrated by the findings that HIF-1a null glial tumors
grow slower at heterotopic implantation sites but faster at or-
thotopic sites (Blouw et al., 2003). Whatever the molecular
mechanism, these data show that HIFs have dual—even oppo-
site—activities in tumor growth.
Medical implications
Our findings may have implications for the development of an-
ticancer therapies. Inhibition of HIF has been proposed to be
an attractive novel treatment to deprive the tumor cell of oxy-
gen and nutrients by suppressing tumor angiogenesis, while at
the same time disabling the mechanisms of the tumor to sur-
vive in a hostile microenvironment (Kung et al., 2000; Ratcliffe
et al., 2000; Zhong et al., 2000). However, based on the present
study, some caution is warranted to block HIF-2α in cancer, as
it may bear a risk that individual tumor clones might become
less dependent on vascular supply and develop resistance to
stress-induced apoptosis, which would promote—instead of
suppress—tumor growth.
Experimental procedures
Cell culture and tumor experiments
Generation of ES cell-derived tumors was performed as described (Carmel-
iet et al., 1998). GS9L cells were stably transfected with different HIF ex-
pression constructs (HIF-1a, HIF-2a, and HIF-dn in pcDNA-3 [Elvert et al.,
2003]) and clonally selected. Individual clones (106 cells) were used for tu-
mor formation as described (Damert et al., 1997). To construct the recombi-
nant lentiviral vectors, HIF-2a and HIF-dn cDNA were subcloned in theCANCER CELL : AUGUST 2005
A R T I C L EPlenti6/UbC vector, and viral particles were produced using ViraPower Len-
tiviral Expression System (Invitrogen) according to the manufacturer’s direc-
tions. Cells were selected with 50 g/ml of blasticidin and, after 5 days,
with 10 g/ml; the polyclonal pool of resistant cells was used for all experi-
ments. To avoid any phenotypic change, polyclonal cells were used until
passage 5 after infection. Gene expression was analyzed by RT-PCR (for
primer sequence, see the Supplemental Experimental Procedures) or by
Western blotting using antibodies specific for HIF-1α (Novus Biologicals,
Littleton, CO), HIF-2α (Novus Biologicals), or FLAG (M2; Sigma-Aldrich,
Saint-Louis, MO). Glioblastoma cell lines were kindly provided by M. West-
phal (Hamburg). Transient siRNA transfection was performed with Oligofec-
tamine using the control (SIMA), HIF-1a, and HIF-2a sequence as described
(Berra et al., 2003; Sowter et al., 2003). All animal studies were reviewed
and approved by the Institutional Animal Care and Use Committee for Medi-
cal Ethics and Clinical Research of the University of Leuven, the Regier-
ungspräsidium Freiburg, or the University of Harvard and were performed
according to the national guidelines for animal experiments.
Intravital microscopy
Intravital microscopy of ES cell-derived tumors in dorsal skin chambers was
performed as described (Carmeliet et al., 1998). Mice with 17 day old tu-
mors (8–10 mm in diameter) were injected intravenously with FITC-dextran
(2 million MW), and vessel architecture was recorded using epi-illumination
microscopy. Vessel diameter, vessel density (defined as the total length of
vessels per unit area; cm/cm2), and vascular volume (defined as the total
volume of vessels per unit area; m3/m2) were analyzed offline. Local tis-
sue pO2 was quantified by measuring the O2-dependent phosphorescence
quenching of albumin-bound palladium meso-tetra-(4-carboxyphenyl)-por-
phyrin.
Histology and apoptosis
All methods for histology, immunostaining, TUNEL staining, and in situ hy-
bridization have been described (Carmeliet et al., 1996, 1998). Vascular
density of tumors was quantified after staining of endothelial cells, using
antibodies against CD34 (BD Pharmingen, San Diego, CA) or CD31 (Phar-
mingen), as the percentage of area surrounded by endothelial cells (vascular
lumen) per optical field (1.345 mm2) using the Quantimet Q600 imaging
system and the Soft Imaging Analysis system (Soft Imaging System GmbH,
Muenster, Germany). Morphometric analysis was performed by counting
the number of small vessels (diameter < 35 m for teratoma; area < 250
m2 for GS9L tumors), medium-sized vessels (diameter between 35 and 90
m for teratoma; area between 250 and 750 m2 for GS9L tumors), and
large vessels (diameter > 90 m for teratoma; area > 750 m2 for GS9L
tumors) per optical field in at least 25 randomly chosen optical fields per
tumor. To analyze apoptosis by immunohistochemistry, we used antibodies
recognizing activated caspase-3 (Promega, Madison, WI). Apoptosis was
measured by quantification of cytoplasmic histone-associated DNA frag-
ments (mono- and oligonucleosomes) and confirmed by TUNEL staining
(Carmeliet et al., 1998). Apoptosis of the polyclonal pool of infected cells,
exposed to 30 hr of 2% O2, was analyzed by flow cytometry after labeling
the cells with propidium iodide and annexin V-FITC, as described (Chen et
al., 2005). Addition of the apoptotic compound staurosporine (Sigma) was
used as positive control (data not shown).
Statistical analysis
Results are represented as mean ± standard error of the mean (SEM). Com-
parisons of values were made using a nonparametric Mann-Whitney U test,
Student’s t test, or ANOVA, as indicated. Significance was assumed at
p < 0.05.
Supplemental data
The Supplemental Data include Supplemental Results, Supplemental Ex-
perimental Procedures, five figures, and four tables and can be found with
this article online at http://www.cancercell.org/cgi/content/full/8/2/131/
DC1/.
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